JPMorgan analyst Lisa Gill believes CVS Health (CVS) is close to a settlement with the Federal Trade Commission regarding the lawsuit the agency brought against pharmacy benefit managers in September of 2024. The settlement is likely to be similar to the one the FTC reached with Cigna (CI), the analyst tells investors in a research note. JPMorgan believes a settlement with CVS would resolve the FTC’s concerns around pharmacy benefit manager practices. It does not anticipate any financial penalty and thinks the news will remove an overhang on the stock. The firm has an Overweight rating on CVS Health.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Sonoma announces U.S. retail launch of advanced burn relief hydrogel
- CVS Health put volume heavy and directionally bearish
- CVS Health Adds Veteran Finance Leader to Board
- Novo Nordisk (NVO) Wins FDA Nod for High-Dose Wegovy amid Surging Obesity Drug Demand
- CVS, Nio, WM: Trending Analyst Moves Investors Must See